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Abstract. Concerning the actual significance level, we investigate the commonly
used combined test procedures of meta-analysis, which contain the choice of the
model, in which the analysis is carried out, and the commonly used tests for
treatment effect in the fixed and random effects model, and some new combined test
procedures, which use an alternative test statistic in the random effects model or the
t-distribution as test distribution of the commonly used test statistics. A simulation
study indicates that the new combined test procedures are better with respect to a
prescribed significance level.
1. Introduction
In this paper we consider the test for treatment effect in the meta-analysis of controlled
clinical trials, i. e. we want to judge if an overall treatment effect is present given
stochastically independent study-specific estimates of the treatment effect. The test for
treatment effect is carried out either in the fixed effects model of meta-analysis assuming
homogeneous treatment effects in all clinical trials or in the random effects model of meta-
analysis if heterogeneity of the study-specific treatment effects is present. Before using the
test for treatment effect one usually makes a decision which of the two models one takes
and this decision may affect the performance of the test for treatment effect in the chosen
model.
2Often, one can find the proposal that the choice of the model should be based on the test
of homogeneity, cf. for instance [1]. But the test of homogeneity in most cases has too low
power to detect differences between the study-specific treatment effects and the false use of
the fixed effects model, if heterogeneity is present, can lead to a substantial increase of the
type I error rate of the commonly used test for treatment effect as pointed out in [2].
Another criterion for the choice between the two models is given in [3] where it is
recommended to use the fixed effects model if the method of moments estimator of the
between-study variance proposed in [4] yields a negative estimate, and if the estimated
value of the between-study variance is positive, the random effects model should be used.
As tests for treatment effect we consider the commonly used ones in the fixed effects and
in the random effects model, respectively, and the alternative test proposed in [5] for the
random effects model. It is known that the commonly used tests for treatment effect may
lead to a large number of unjustified significant evidences even if one carries out the
analysis in the correct model, cf. for instance [6] and [7]. So, we will compare the
commonly used decision rules and some new decision rules, which contain either the
alternative test from [5] or the commonly used test statistics of the test for treatment effect
but instead of the standard normal distribution an appropriate t-distribution is used as test
distribution, cf. [8].
2. The test statistics
Let us consider k controlled clinical trials and let us denote by θ θ1, ,K k the one-
dimensional parameters of interest, where each parameter stands for the treatment effect in
a study. In each trial an estimate of the parameter θ i , say $θ i , is available with an estimate
of the variance of $θ i , say ( )$ $σ θ2 i . It is usually assumed that the study-specific estimators
$θ i , are at least approximately normally distributed and (nearly) unbiased. If all study-
specific treatment effects are equal, i. e. it holds θ θ θ1 = = =K k , then the feasible
estimator of the overall treatment effect θ in the fixed effects model is given by
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The test statistic for the test for treatment effect, i. e. the hypothesis is H0 0:θ = , is given
by
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and the hypothesis H0 is rejected at level α if the observed absolute value of T1 exceeds the
(1-α/2)-quantile of the standard normal distribution denoted by u1 2−α / .
The assumption of homogeneous treatment effects can be formally tested using the test
statistic
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which is at least approximately χ2-distributed with (k-1) degrees of freedom under the
hypothesis of homogeneity, cf. [9], and the hypothesis of homogeneity is rejected at level α
if the observed value of Q exceeds the (1-α)-quantile of the χ2-distribution with (k-1)
degrees of freedom denoted by χ αk − −1 12 ; .
In the random effects model the study-specific treatment effects θ i i k, , , ,= 1K may
vary, and it is assumed that θ i i k, , , ,= 1K are stochastically independent normally
distributed random variables with mean θ and variance τ2 . Then, the marginal distribution
of the study-specific estimators $θi is the normal distribution with mean θ and variance
( )τ σ θ2 2+ $ i , cf. [3]. The parameter τ 2 is often called between-study variance.
The feasible estimator of the overall treatment effect θ in the random effects model is
given by
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where $τ2 is a nonnegative estimator of the between-study variance τ2 , for instance the
truncated versions of the DerSimonian-Laird estimator $τ DSL2 or of the restricted maximum
likelihood estimator $τ REML2 , cf. [1].
4The test statistic for H0 0:θ = is then given by
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and the hypothesis H0 is rejected at level α if the observed absolute value of T2 exceeds
u1 2−α / .
In the random effects model Hartung, cf. [5], derived a new estimator for the variance of
the best linear unbiased estimator of the overall treatment effect which is stochastically
independent of the best estimator of θ and is distributed as a multiple of a χ2-distribution
with (k-1) degrees of freedom. Thus, an alternative test statistic of the test for treatment
effect in the random effects model can be constructed. The feasible alternative test statistic
is given by
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and the hypothesis H0 0:θ = is rejected at level α if the observed absolute value of T3
exceeds the (1-α/2)-quantile of the t-distribution with (k-1) degrees of freedom denoted by
tk − −1 1 2; /α .
3. Combined test procedures
In table 1 we put together the combined test procedures for the hypothesis H0 0:θ = which
we will investigate.
The test ψ1 reflects the usual procedure that the model choice depends on the test of
homogeneity and for the test for treatment effect the commonly used test statistic is used
with the standard normal distribution as test distribution. The decision rule of the test ψ 2 is
quite similar to the previous one but instead of the standard normal distribution the t-
distribution with (k-1) degrees of freedom is used as test distribution, cf. [8].
The test ψ 3 coincides with the proposal in [3] that the model choice should be dependent
on the sign of the DerSimonian-Laird estimator $τ DSL2 and then the commonly used test is
5applied in the corresponding model. The decision rule of the test ψ 4 resembles the proposal
in [3] with the difference that the t-distribution is used as test distribution.
The test ψ5 is the alternative test proposed in [5] for the random effects model and we
will investigate this test if it is always used irrespective of the true underlying model. In
contrast to the test ψ5, the test ψ 6 requires the additional consideration of the commonly
used test of the fixed effects model if the DerSimonian-Laird estimator of the between-
study variance does not yield a positive estimate. The test ψ 6 is motivated for correcting a
possible anti-conservative attitude of the test ψ5 if the between-study variance is small.
Table 1: Decision rules of the test for treatment effect
Test Decision rule: Reject H0 0:θ = if
ψ1 ( )Q and T uk≤ >− − −χ α α1 12 1 1 2; / or ( )Q and T uk> >− − −χ α α1 12 2 1 2; /
ψ 2 ( )Q and T tk k≤ >− − − −χ α α1 12 1 1 1 2; ; /  or ( )Q and T tk k> >− − − −χ α α1 12 2 1 1 2; ; /
ψ 3 ( )$ /τ αDSL and T u2 1 1 20≤ > − or ( )$ /τ αDSL and T u2 2 1 20> > −
ψ 4 ( )$ ; /τ αDSL kand T t2 1 1 1 20≤ > − −  or ( )$ ; /τ αDSL kand T t2 2 1 1 20> > − −
ψ5 T tk3 1 1 2> − −; /α
ψ 6 ( )$ ; /τ αDSL kand T t2 3 1 1 20> > − −  or
( )$ / ; /τ α αDSL kand T u and T t2 1 1 2 3 1 1 20≤ > >− − −
4. Simulation study
In a simulation study we investigate the six decision rules from table 1 concerning their
actual significance level given a nominal significance level of α = 0 05. . We consider the
meta-analysis of 10 controlled clinical trials where in each trial a new treatment is
compared to a standard treatment. As parameter of interest we choose the risk difference,
i. e. the difference of the probabilities of success of the two treatments. The probabilities of
success are randomly chosen from the interval [0.5 ; 0.8] under the hypothesis that the
overall risk difference is equal to zero.
6We present the results for three different patterns of sample sizes where in each pattern
the number of patients in each study and treatment group is equal and as different sample
sizes we consider nij = 10, 20, and 40 for i=1, ..., 10 clinical trials and j =1, 2 treatment
groups in each trial. As values of the between-study variance τ2 we take 0, 0.01, 0.1, and 1.
The between-study variance τ2 is always estimated using the truncated version of the
DerSimonian-Laird estimator.
The results of the simulation study are given in table 2 where each reported estimated
type I error rate is based on 10,000 runs of the corresponding model.
Table 2: Estimated type I error rates (in %) for the hypothesis H0 0:θ = in the meta-
analysis of 10 controlled clinical trials using the decision rules from table 1 and the
parameter of interest is the risk difference
k = 10 Tests for H0 0:θ = at level α = 0 05.
nij τ2 ψ1 ψ 2 ψ 3 ψ 4 ψ5 ψ 6
10 0 6.75 3.44 5.21 2.47 5.95 4.41
0.01 9.26 5.36 6.72 3.68 6.33 5.43
0.1 9.84 6.36 8.40 5.10 5.29 5.41
1 8.58 5.29 8.57 5.28 5.10 5.10
20 0 5.95 3.12 4.63 2.36 5.53 3.81
0.01 9.03 5.21 6.54 3.35 5.31 4.75
0.1 8.27 5.30 8.03 4.94 5.03 5.06
1 8.72 5.41 8.72 5.41 5.43 5.43
40 0 5.13 2.55 4.15 1.93 5.30 3.38
0.01 9.80 5.90 7.17 3.93 4.97 4.84
0.1 8.41 5.14 8.38 5.13 5.02 5.02
1 8.35 5.27 8.35 5.27 5.21 5.21
From table 2 we see that the commonly used test procedures ψ1 and ψ 3 , which contain
the model choice between the fixed and the random effects model as well as the standard
normal distribution as test distribution of the test for treatment effect, have estimated type I
error rates up to nearly 10% if heterogeneity is present, and even if the sample sizes within
the studies increase, both tests remain rather anti-conservative. For large values of τ2 both
tests have nearly identical estimated type I error rates but for smaller positive values the test
7ψ 1 always yields the larger estimated type I error rates. For τ2 0= we observe that the
estimated type I error rates of the tests ψ 1 and ψ 3 decline for growing sample sizes within
the studies. So, for small sample sizes within the studies the test ψ 3 has acceptable results
concerning the prescribed significance level and becomes a bit conservative for increasing
sample sizes. The test ψ 1 , however, attains the nominal significance level for larger sample
sizes, whereas for smaller sample sizes the test is anti-conservative.
Due to its construction the combined tests ψ 2 and ψ 4 , which use the t-distribution as test
distribution of the test for treatment effect, have always estimated type I error rates which
are below the estimated type I error rates of the tests ψ1 and ψ 3 . Moreover, the test ψ 2
always has larger estimated type I error rates than the test ψ 4 . If no or less heterogeneity is
present, the tests ψ 2 and ψ 4 can become rather conservative, whereas for growing between-
study variance both tests yield satisfactory and nearly identical results concerning the
prescribed significance level.
The test ψ5 almost always has estimated type I error rates near the prescribed level
irrespective of the true underlying model. Only for small sample sizes and less
heterogeneity the test is a bit anti-conservative. In this situation the test ψ 6 leads to an
improvement concerning the actual significance level. For growing between-study variance
both tests, ψ5 and ψ 6 , are nearly identical.
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